Cardinal Health extends CVS deal. What it means for Cardinal Health stock
Published on 10/03/2026 at 10:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
On October 1, 2026, Cardinal Health announced a binding letter of intent to extend its pharmaceutical distribution agreements with CVS Health through June 30, 2032, according to the company release distributed by PR Newswire. Cardinal Health stock stood at EUR 202.90 in weekend trading at Lang & Schwarz at 10:06 a.m. CEST on October 3, 2026, a 0.00 percent change versus the EUR 202.90 close at Lang & Schwarz on October 2, 2026.
Weekend trading remains unchanged
The EUR 202.90 price was unchanged from the EUR 202.90 close at Lang & Schwarz on October 2, 2026. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CEST is shown by the continuously updated real-time quote of Cardinal Health stock.
CVS agreement extends through June 2032
The letter of intent covers Cardinal Health’s existing distribution agreement with CVS Health and reflects continuation of the current scope of distribution services, the PR Newswire release said. Cardinal Health also reaffirmed fiscal year 2027 non-GAAP earnings per share guidance of 13 percent to 15 percent growth, or USD 12.40 to USD 12.60. The company said the growth rates are based on adjusted fiscal year 2026 results excluding the fiscal year 2026 benefit from an IEEPA tariff refund.
Next Xetra session
The next Xetra session is scheduled for October 5, 2026. Cardinal Health’s release said further updates may be provided during the company’s first-quarter earnings call on November 5, 2026.
